https://www.selleckchem.com/pr....oducts/Dasatinib.htm
HLA-DQA1*050505 differs from HLA-DQA1*05050107 by one nucleotide substitution in codon 111 in exon 3.Purpose We defined the Minimal Clinically Important Improvement (MCII) and Worsening (MCIW) for the Patient Activity Scale (PAS)-II (range 0-1, a recommended patient-reported outcome measuring rheumatoid arthritis disease activity. Methods Data from Forward, The National Databank for Rheumatic Diseases from four 6-month data collection periods was utilized. Both anchor-based and distribution-based methods were used to estimate the MC
Like
Comment
Share
